Trials

[1] StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.

[2] ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration

[3] distant metastatic retinoblastoma without central nervous system involvement

[4] study on the change of retinal thickness and choroidal thickness and correlative factors for macular edema after ranibizumab injection

[5] effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in korea

[6] ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

[7] combined approach to the surgical treatment of patients with prolifera-tive stage of diabetic retinopathy

[8] an unusual case of self-inflicted multiple needles injuries to eye

[9] immediate sequential bilateral intravitreal injections: an indian perspective

[10] Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: A case report

[11] [Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase].

[12] Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

[13] Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

[14] Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.

[15] Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

[16] Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

[17] Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

[18] intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade

[19] ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration

[20] ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis

[21] daño renal asociado a la administración intravítrea de ranibizumab

[22] a novel machine learning algorithm to automatically predict visual outcomes in intravitreal ranibizumab-treated patients with diabetic macular edema

[23] a comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (macugen), ranibizumab (lucentis) and bevacizumab (avastin)

[24] intravitreal ranibizumab for stage iv proliferative sickle cell retinopathy: a first case report

[25] foveal exudative macroaneurysm treated with intravitreal ranibizumab

[26] antiproliferative, apoptotic, and autophagic activity of ranibizumab, bevacizumab, pegaptanib, and aflibercept on fibroblasts: implication for choroidal neovascularization

[27] study on the change of retinal thickness and choroidal thickness and correlative factors for macular edema after ranibizumab injection

[28] conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

[29] prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration

[30] effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in korea

[31] evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab

[32] ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

[33] long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections

[34] comparisons of efficacy of intravitreal aflibercept and ranibizumab in eyes with diabetic macular edema

[35] visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

[36] Short-term reactivation of retinopathy of prematurity following primary ranibizumab treatment.

[37] Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: A case report